N-[5-[2-(2-methoxyanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[5-[2-(2-methoxyanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide
• 化学式: C₂₁H₁₈N₄O₂S₂
• 分子量: 422.5
• InChiKey: DLLKDLFPBARGCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  133
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION
  申请人：JACKSON Paul Francis

  公开号：US20120302573A1

  公开（公告）日：2012-11-29

  This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.

  这项发明涉及预防、治疗或改善由MMP9和/或MMP13介导的综合症、紊乱或疾病的方法，包括向需要的受试者施用本说明书示例部分列出的化合物的有效量，或其形式、组合或药物。治疗和/或预防的疾病包括类风湿关节炎。
• Ligase E3 RNF185 inhibitors and uses thereof
  申请人：Commissariat à l'Énergie Atomique et aux Énergies Alternatives

  公开号：EP2835423A1

  公开（公告）日：2015-02-11

  The present relates to the use of an E3 ligase RNF185 inhibitor for treating cystic fibrosis and chronic obstructive pulmonary disease.

  本发明涉及一种用于治疗囊性纤维化和慢性阻塞性肺病的 E3 连接酶 RNF185 抑制剂。
• A CFTR CORRECTOR FOR THE TEATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE
  申请人：Università Degli Studi Di Padova

  公开号：EP2925317B1

  公开（公告）日：2019-09-04
• LIGASE E3 RNF185 INHIBITORS AND USES THEREOF
  申请人：Commissariat à l'Energie Atomique et aux Energies Alternatives

  公开号：EP3030657B1

  公开（公告）日：2018-07-18
• Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof
  申请人：Verkman Alan

  公开号：US20080318984A1

  公开（公告）日：2008-12-25

  The invention provides compositions, pharmaceutical preparations and methods for correcting cellular processing (e.g., folding, trafficking, or post-translational modification) of a mutant-cystic fibrosis transmembrane conductance regulator protein (e.g., ΔF508 CFTR) that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more aminobenzothiazole-containing compounds, aminoarylthiazole-containing compounds, quinazolinylaminopyrimidinone-containing compounds, bisaminomethylbithiazole-containing compounds, or phenylaminoquino-line-containing compounds of the invention, or an analog or derivative thereof.